Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-19T14:10:48.078Z Has data issue: false hasContentIssue false

Chapter 11 - Fertility Preservation in Young Adults with Gastrointestinal and Hematological Malignancies

from Section 3 - Fertility Preservation in Cancer and Non-Cancer Patients

Published online by Cambridge University Press:  27 March 2021

Jacques Donnez
Affiliation:
Catholic University of Louvain, Brussels
S. Samuel Kim
Affiliation:
University of Kansas School of Medicine
Get access

Summary

Cancer is one of the most important public health problems all around the world. It is the second leading cause of death globally. Thousands of young women are diagnosed with different types of hematological and solid malignancies every year, and exposed to cytotoxic chemotherapy regimens and radiation [1]. In the United States, the ten leading cancer types in females are breast, lung and bronchus, colon and rectum, thyroid, melanoma, non-Hodgkin’s lymphoma (NHL), pancreas, leukemia, and kidney and renal pelvis [2]. In Europe, hematological malignancies account for around 9% of all cancers and are the fourth most frequently diagnosed cancer in both men (after prostate, lung, and colorectal) and women (after breast, lung, and colorectal) [3]. For all cancers combined, the five-year relative survival rate is 68%. The survival is highest for prostate cancer (99%), melanoma of the skin (92%), and female breast cancer (90%) and lowest for cancers of the pancreas (8%), lung (18%), and liver (18%)

Type
Chapter
Information
Fertility Preservation
Principles and Practice
, pp. 116 - 126
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Oktem, O, Urman, B. Options of fertility preservation in female cancer patients. Obstet Gynecol Surv, 2010;65(8):531542.CrossRefGoogle ScholarPubMed
Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2018. CA Cancer J Clin, 2018;68(1):730.CrossRefGoogle ScholarPubMed
Smith, A, Howell, D, Patmore, R, Jack, A, Roman, E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer, 2011;105(11):16841692.CrossRefGoogle ScholarPubMed
Oktem, O, Kim, SS, Selek, U, Schatmann, G, Urman, B. Ovarian and uterine functions in female survivors of childhood cancers. Oncologist, 2018;23(2):214224.Google Scholar
Plowchalk, DR, Mattison, DR. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxicol Appl Pharmacol, 1991;107(3):472481.CrossRefGoogle ScholarPubMed
Oktem, O, Oktay, K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer, 2007;110(10):22222229.Google Scholar
Meirow, D, Dor, J, Kaufman, B et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod, 2007;22(6):16261633.Google Scholar
Bildik, G, Akin, N, Senbabaoglu, F et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod, 2015;30(12):29122925.Google Scholar
Kalich-Philosoph, L, Roness, H, Carmely, A et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med, 2013;5(185):185ra162.Google Scholar
Morgan, S, Lopes, F, Gourley, C, Anderson, RA, Spears, N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS One, 2013;8(7):e70117.Google Scholar
Himelstein-Braw, R, Peters, H, Faber, M. Morphological study of the ovaries of leukaemic children. Br J Cancer, 1978;38(1):8287.CrossRefGoogle ScholarPubMed
Epstein, RJ. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol, 1990;8(12):20622084.CrossRefGoogle ScholarPubMed
Antal, Z, Sklar, CA. Gonadal function and fertility among survivors of childhood cancer. Endocrinol Metab Clin North Am, 2015;44(4):739749.Google Scholar
Oktem, O, Oktay, K. The ovary: anatomy and function throughout human life. Ann N Y Acad Sci, 2008;1127:19.Google Scholar
Oktem, O, Oktay, K. Preservation of menstrual function in adolescent and young females. Ann N Y Acad Sci, 2008;1135:237243.Google Scholar
Bines, J, Oleske, DM, Cobleigh, MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol, 1996;14(5):17181729.Google Scholar
Wallace, WH, Thomson, AB, Kelsey, TW. The radiosensitivity of the human oocyte. Hum Reprod, 2003;18(1):117121.Google Scholar
Ashwood-Smith, MJ, Edwards, RG. DNA repair by oocytes. Mol Hum Reprod, 1996;2(1):4651.Google Scholar
Adriaens, I, Smitz, J, Jacquet, P. The current knowledge on radiosensitivity of ovarian follicle development stages. Hum Reprod Update, 2009;15(3):359377.Google Scholar
Jaroudi, S, Kakourou, G, Cawood, S et al. Expression profiling of DNA repair genes in human oocytes and blastocysts using microarrays. Hum Reprod, 2009;24(10):26492655.Google Scholar
Himelstein-Braw, R, Peters, H, Faber, M. Influence of irradiation and chemotherapy on the ovaries of children with abdominal tumours. Br J Cancer, 1977;36(2):269275.Google Scholar
Oktem, O, Oktay K. Preservation of menstrual function in adolescent and young females. Ann N Y Acad Sci, 2008; 1135:237–243.CrossRefGoogle Scholar
Green DM, Kawashima T, Stovall M et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Cli Oncol, 2009;27(16):2677–2685.Google Scholar
Critchley, HO, Wallace, WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr, 2005;34:6468.CrossRefGoogle ScholarPubMed
Sudour, H, Chastagner, P, Claude, L et al. Fertility and pregnancy outcome after abdominal irradiation that included or excluded the pelvis in childhood tumor survivors. Int J Radiat Oncol Biol Phys, 2010;76(3):867873.Google Scholar
Beneventi, F, Locatelli, E, Giorgiani, G et al. Gonadal and uterine function in female survivors treated by chemotherapy, radiotherapy, and/or bone marrow transplantation for childhood malignant and non-malignant diseases. BJOG, 2014;121(7):856865; discussion 865.Google Scholar
Hawkins, MM, Smith, RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer, 1989;43(3):399402.Google Scholar
Knopman, JM, Papadopoulos, EB, Grifo, JA et al. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol, 2010;11(5):490–498.Google Scholar
Critchley, HO, Bath, LE, Wallace, WH, Radiation damage to the uterus – review of the effects of treatment of childhood cancer. Hum Fertil (Camb), 2002;5(2):61–66.Google Scholar
Norwitz, ER, Stern, HM, Grier, H, Lee-Parritz, A. Placenta percreta and uterine rupture associated with prior whole body radiation therapy. Obstet Gynecol, 2001;98(5 Pt 2):929931.Google ScholarPubMed
Teh, WT et al. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int, 2014;2014:482968.Google Scholar
Barton, SE et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol, 2013; 14(9):873881.Google Scholar
Gill, S, Blackstock, AW, Goldberg, RM, Colorectal cancer. Mayo Clin Proc, 2007; 82(1):114129.Google Scholar
Maindrault-Goebel, F, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer, 1999; 35(9):13381342.Google Scholar
Fuchs, CS et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICCC Study. J Clin Oncol, 2007; 25(30):47794786.CrossRefGoogle ScholarPubMed
Douillard, JY et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med, 2013; 369(11):10231034.Google Scholar
Cercek, A et al. Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer. Clin Colorectal Cancer, 2013;12(3):163167.Google Scholar
Wan, J et al. Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer. Clin Colorectal Cancer, 2015;14(1):3134.CrossRefGoogle ScholarPubMed
Utsunomiya, T et al. A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. Int J Oncol, 2008;32(5):9911000.Google Scholar
Tanaka, T et al. Irinotecan HCl, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. Oncol Rep, 2008;19(5):11231133.Google Scholar
Zamah, AM et al. Will imatinib compromise reproductive capacity? Oncologist, 2011;16(10):14221427.Google Scholar
Christopoulos, C, Dimakopoulou, V, Rotas, E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med, 2008;358(10):10791080.CrossRefGoogle ScholarPubMed
Gonfloni, S et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy induced death. Nat Med, 2009;15(10):11791185.Google Scholar
Kerr, JB et al. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med, 2012;18(8):11701172; author reply 1172–1174.Google Scholar
Bildik, G C-Abl is not activated in DNA damage-induced and Tap63-mediated oocyte apoptosis in human ovary. Cell Death Dis, 2018;9(10):943.Google Scholar
Jou, E, Rajdev, L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol, 2016;22(20):48124823.Google Scholar
Berliere, M et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer, 2008;8:56.Google Scholar
Nabholtz, JPT, Mackey, J. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study. Proc Annu Meet Am Soc Clin Oncol, 2002;141 (Abstract).Google Scholar
Hortobagyi, GN et al. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr, 1986(1):105–109.Google Scholar
Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med, 1985;312(23):14651472.CrossRefGoogle Scholar
Krook, JE et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med, 1991;324(11):709715.Google Scholar
Tveit, KM et al. Randomized controlled trial of postoperative radiotherapy and short-term time scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg, 1997;84(8):11301135.Google Scholar
O’Connell, MJ et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med, 1994;331(8):502507.Google Scholar
Tepper, JE et al. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol, 1997;15(5):20302039.CrossRefGoogle ScholarPubMed
Tepper, JE et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control–final report of intergroup 0114. J Clin Oncol, 2002;20(7):17441750.Google Scholar
Fietkau, R, Rodel, C. [Postoperative radiochemotherapy of rectal carcinoma reduces the incidence of locoregional recurrences but does not improve the prognosis of patients–the results of a randomized study of the NSABP-R02. National Surgical Adjuvant Breast and Bowel Project Protocol]. Strahlenther Onkol, 2000;176(8):381382.Google Scholar
Wolmark, N et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst, 2000;92(5):388396.CrossRefGoogle ScholarPubMed
Lee, JH et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report. J Clin Oncol, 2002;20(7):17511758.Google Scholar
Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum, 1993;36(6):564–572.CrossRefGoogle Scholar
Sauer, R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004;351(17):1731–1740.Google Scholar
Behringer, K et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol, 2013;31(2):231–239.Google Scholar
Jadoul P, Kim SS, IP Committee, Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet, 2012;29(6):479–487.Google Scholar
Kiserud CE et al. Post-treatment parenthood in Hodgkin’s lymphoma survivors. Br J Cancer, 2007;96(9):1442–1449.Google Scholar
Hodgson DC et al. Fertility among female Hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy. Hematol Oncol, 2007;25(1):11–15.Google Scholar
Behringer K et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol, 2012;23(7):1818–1825.Google Scholar
De Bruin ML et al. Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood, 2008;111(1):101–108.Google Scholar
Donnez J et al. Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. Ann Med, 2011;43(6):437–450.Google Scholar
Bittinger SE et al. Detection of Hodgkin lymphoma within ovarian tissue. Fertil Steril, 2011;95(2):803 e3–6.Google Scholar
Chorlton I, Norris HJ, King FM. Malignant reticuloendothelial disease involving the ovary as a primary manifestation: a series of 19 lymphomas and 1 granulocytic sarcoma. Cancer, 1974;34(2):397–407.3.0.CO;2-0>CrossRefGoogle Scholar
Meirow D et al. Ovarian tissue banking in patients with Hodgkin’s disease: is it safe? Fertil Steril, 1998;69(6):996–998.Google Scholar
Seshadri T et al. Lack of evidence of disease contamination in ovarian tissue harvested for cryopreservation from patients with Hodgkin lymphoma and analysis of factors predictive of oocyte yield. Br J Cancer, 2006;94(7):1007–1010.CrossRefGoogle Scholar
Elis A et al. Fertility status among women treated for aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma, 2006;47(4):623–627.Google Scholar
Seshadri T et al. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leuk Res, 2006;30(4):483–485.Google Scholar
Shaw JM et al. Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients. Hum Reprod, 1996;11(8):1668–1673.CrossRefGoogle Scholar
Dolmans MM et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood, 2010;116(16):2908–2914.Google Scholar
Dolmans MM et al. Efficacy of in vitro fertilization after chemotherapy. Fertil Steril, 2005;83(4):897–901.Google Scholar
Gellert SE et al. Transplantation of frozen thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet, 2018;35(4):561–570.Google Scholar
Bastings L et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update, 2013;19(5):483–506.Google Scholar
Cuellar S et al. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract, 2018;24(6):433–452.Google Scholar
Carlsson IB et al. Kit ligand and c-Kit are expressed during early human ovarian follicular development and their interaction is required for the survival of follicles in long-term culture. Reproduction, 2006;131(4):641–649.Google Scholar
Kim SY et al. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network. Cell Death Differ, 2013;20(8):987–997.CrossRefGoogle Scholar
Tuppi M et al. Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63. Nat Struct Mol Biol, 2018;25(3):261–269.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×